Ozempic maker Novo Nordisk isn't just Europe's second-most valuable company. It is also singlehandedly boosting Denmark's economy.

• Ozempic-maker Novo Nordisk is Europe's second-largest company by market capitalization.
• It's also boosting Denmark's economy all on its own.
• Denmark's GDP grew 1.7% in 1H 2023. It would've contracted by 0.3% if not for the pharma sector.

Weight loss drug Ozempic is such a blockbuster hit that its maker, Novo Nordisk, has become one of the most high-profile companies in Europe.

Novo Nordisk's share price is up over 40% this year, taking its market capitalization to 2.3 trillion Danish Kroner, or $328 billion. In comparison, the market cap of LVMH Moët Hennessy Louis Vuitton — Europe's most valuable company now — is 376.95 billion euros or $402 billion.